1
|
MLL targets SET domain methyltransferase activity to Hox gene promoters.
|
Mol Cell
|
2002
|
8.17
|
2
|
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.
|
Cell
|
2005
|
6.12
|
3
|
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.
|
Mol Cell
|
2004
|
6.08
|
4
|
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
|
Mol Cell Biol
|
2004
|
3.62
|
5
|
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
|
Blood
|
2007
|
3.60
|
6
|
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
|
Proc Natl Acad Sci U S A
|
2005
|
3.37
|
7
|
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
|
Nat Chem Biol
|
2012
|
3.15
|
8
|
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.
|
PLoS Genet
|
2012
|
2.94
|
9
|
MLL associates specifically with a subset of transcriptionally active target genes.
|
Proc Natl Acad Sci U S A
|
2005
|
2.87
|
10
|
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
|
Cancer Cell
|
2010
|
2.50
|
11
|
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
|
Cancer Res
|
2005
|
2.45
|
12
|
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.
|
Cancer Cell
|
2011
|
2.01
|
13
|
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
|
Blood
|
2011
|
1.99
|
14
|
The pathogenesis of mixed-lineage leukemia.
|
Annu Rev Pathol
|
2011
|
1.95
|
15
|
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
|
Blood
|
2009
|
1.90
|
16
|
Interaction of MLL amino terminal sequences with menin is required for transformation.
|
Cancer Res
|
2007
|
1.82
|
17
|
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease.
|
EMBO J
|
2005
|
1.79
|
18
|
Dimerization of MLL fusion proteins immortalizes hematopoietic cells.
|
Cancer Cell
|
2003
|
1.79
|
19
|
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.
|
Proc Natl Acad Sci U S A
|
2006
|
1.67
|
20
|
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin.
|
Oncogene
|
2005
|
1.64
|
21
|
Identification and characterization of Hoxa9 binding sites in hematopoietic cells.
|
Blood
|
2011
|
1.63
|
22
|
Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice.
|
J Virol
|
2005
|
1.46
|
23
|
The advent of targeted therapeutics and implications for pathologists.
|
Am J Clin Pathol
|
2002
|
1.38
|
24
|
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
|
Exp Hematol
|
2010
|
1.35
|
25
|
MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription.
|
Mol Cell Biol
|
2009
|
1.33
|
26
|
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia.
|
Int J Hematol
|
2007
|
1.26
|
27
|
The PHD fingers of MLL block MLL fusion protein-mediated transformation.
|
Blood
|
2008
|
1.18
|
28
|
HOX proteins and leukemia.
|
Int J Clin Exp Pathol
|
2008
|
1.14
|
29
|
Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins.
|
Methods Mol Biol
|
2009
|
1.13
|
30
|
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
|
Blood
|
2004
|
1.09
|
31
|
ECSASB2 mediates MLL degradation during hematopoietic differentiation.
|
Blood
|
2011
|
0.99
|
32
|
MLL core components give the green light to histone methylation.
|
ACS Chem Biol
|
2006
|
0.99
|
33
|
Acute myeloid leukemia diagnosis in the 21st century.
|
Arch Pathol Lab Med
|
2010
|
0.90
|
34
|
PAFc, a key player in MLL-rearranged leukemogenesis.
|
Oncotarget
|
2010
|
0.89
|
35
|
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.
|
J Biol Chem
|
2012
|
0.89
|
36
|
MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells.
|
Cell Rep
|
2013
|
0.86
|
37
|
Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
|
J Biol Chem
|
2013
|
0.83
|
38
|
Epigenetic dysregulation in cancer.
|
Am J Pathol
|
2009
|
0.82
|
39
|
The role of menin in hematopoiesis.
|
Adv Exp Med Biol
|
2009
|
0.82
|
40
|
The Cancer Genome Anatomy Project: power tools for cancer biologists.
|
Cancer Invest
|
2003
|
0.80
|
41
|
MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
|
Blood
|
2013
|
0.79
|
42
|
Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?
|
Leuk Res
|
2010
|
0.77
|
43
|
Deregulation of the HOXA9/MEIS1 axis in acute leukemia.
|
Curr Opin Hematol
|
2016
|
0.76
|
44
|
MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
|
Cancer Cell
|
2008
|
0.76
|
45
|
Structural basis of multimer-mediated mayhem.
|
Cancer Cell
|
2006
|
0.75
|
46
|
Twenty-first century pathology sign-out.
|
Clin Lab Med
|
2012
|
0.75
|